Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy's First Biosimilar Target Will Be Amgen's Neupogen

This article was originally published in PharmAsia News

Executive Summary

Ranbaxy Laboratories is set to venture into biosimilar development, targeting Amgen's neutropenia treatment Neupogen (filgrastim) as its first generic biologic, the company announced Feb. 7

You may also be interested in...



Dr. Reddy’s Tops Billion Dollar Mark In First Nine Months Of Fiscal 2007

Indian generic drug maker achieved the milestone on acquisitions supported by a “strong and profitable” growth engine.

Hospira, Stada Collaboration To Yield Biosimilar EPO In The EU Ahead Of U.S.

Hospira obtains exclusive distribution rights for Bioceuticals erythropoietin in the EU and will be solely responsible for U.S. development.

Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval

Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel